Advanced Accelerator Applications S.A.

Company report, featuring a PESTLE, Porters Five Forces, 5C, MOST, CATWOE and SWOT analysis

HomeSWOT AnalysisHealth CareAdvanced Accelerator Applications S.A.

Introduction

This report on Advanced Accelerator Applications S.A., part of our research on the world’s 10,000 largest companies, is created and updated at an accelerated pace to guarantee the most current information available.

Full access to this study on Advanced Accelerator Applications S.A. is available only to Premium members.

We identify potential new products and/or services that are separate from the analysis-driven sections, forecast future market trends, and prognosticate synergies between Advanced Accelerator Applications S.A. and other organisations.

Company Description

Advanced Accelerator Applications S.A. is a global biopharmaceutical company headquartered in Saint Genis Pouilly, France. Founded in 2002, the company primarily focuses on the development, production and commercialisation of molecular nuclear medicine therapies for both therapeutic and diagnostic use. Its main products include Lutathera, a peptide receptor radionuclide therapy, and Azedra, an radiotherapeutic drug. Advanced Accelerator Applications primarily serves oncology, endocrinology and neurology markets.

Industry Overview

Advanced Accelerator Applications S.A. operates in the nuclear medicine market, which is worth an estimated $4.5 billion USD. The industry employs approximately 15,000 people in countries across the world, including both developed and developing markets. These employees are based in various countries, including the United States, Germany, Italy, France, Japan, China, and India. Advanced Accelerator Applications S.A. is a leader in the industry, having developed a number of innovative products and services.

Industry Classification

In terms of formal classification, Platform Executive has tagged Advanced Accelerator Applications S.A. as a business operating within the Pharmaceuticals industry.

1. Introduction
2. Company Description
3. Industry Overview
    3.1 Industry Classification
4. Intellectual Property
5. Major Products and Services
6. Key Competitors
7. Stakeholders
8. Value Proposition
9. Customers and Cohorts
10. Competitive Advantages
11. Market Trends
12. Key Performance Indicators
13. Financials (BETA)
    13.1 Highlights
    13.2. Board members
    13.3 Share Performance
    13.4 Income Statement
14. PESTLE Analysis
15. Potential Products/Services
16. Potential Synergies
17. Porter's Five Forces
18. CATWOE Analysis
19. SWOT Analysis
    19.1 Strengths
    19.2 Weaknesses
    19.3 Opportunities
    19.4 Threats
20. 5C Analysis
21. MOST Analysis
22. Innovation Scorecard
23. Appendices

Save to Library

Bookmark (0)

To login to your account click here.

Intellectual Property

Some of the Patents granted to, or relevant to the organisation include the following:

Patent Title: Methods and compositions for imaging and treating tumours
Patent ID: 10,521,897
Date: April 7, 2020

Patent Title: Imaging compositions and methods
Patent ID: 10,518,621
Date: April 14, 2020

Patent Title: Radiopharmaceuticals including peptides and methods of production and use thereof
Patent ID: 10,518,620
Date: April 14, 2020

Patent Title: Radiopharmaceuticals and methods of production and use thereof
Patent ID: 10,518,619
Date: April 14, 2020

Patent Title: Radiopharmaceuticals and methods of production and use thereof
Patent ID: 10,518,618
Date: April 14, 2020

Patent Title: Radiopharmaceuticals and methods of production and use thereof
Patent ID: 10,518,617
Date: April 14, 2020

Patent Title: Method of producing a composite particle
Patent ID: 10,517,353
Date: April 14, 2020

Patent Title: Method of producing a composite particle
Patent ID: 10,517,352
Date: April 14, 2020

Patent Title: Method of producing a composite particle
Patent ID: 10,517,351
Date: April 14, 2020

Patent Title: Radiopharmaceuticals, methods of production and use thereof
Patent ID: 10,511,072
Date: April 7, 2020

Major Products & Services

The main products and/or services commercialised by this business include the following:

Therapeutic Radiopharmaceuticals: Lutathera®, Azedra®, Xofigo®, and Xofigo® Radium-223 Dichloride
Diagnostic Radiopharmaceuticals: Neuroblastoma MIBG Kit
Radiopharmaceutical APIs: Lutetium Lu 177 Dotatate, Lutetium Lu 177 Octreotate, Yttrium Y 90 Dotatate, Technetium Tc 99m Tracers
Radiochemistry Services: Production of Radiopharmaceuticals
Contract Manufacturing Services: Radiopharmaceutical Manufacturing and Packaging
Radiopharmaceuticals Distribution Services: Distribution of Radioactive Materials

Key Competitors

We have identified the following organisations as being key competitors:

Novartis AG
Amgen Inc
Eli Lilly and Company
Bayer AG
Merck & Co Inc
GlaxoSmithKline plc
Johnson & Johnson
AstraZeneca plc
Takeda Pharmaceutical Company Limited
Sanofi S.A.

Unlock this SWOT analysis report

Each detailed study features a PESTLE, Porters Five Forces, 5C, MOST, CATWOE and an expert SWOT analysis, along with a myriad of other sections.

Premium members have FULL ACCESS to this content and approximately 10,000 similar competitive intelligence reports.

Premium membership is just $195 per month, with annual membership at $1,950 / seat.

UNLOCK CONTENT

Key Stakeholders

Stakeholders are individuals or groups who have an interest in a business and/or are affected by its actions.

These stakeholders can have different requirements and expectations from the business, which must be taken into account when making decisions.

By understanding their stakeholders’ requirements, a business can make informed decisions that benefit all involved.

Below is the list of internal and external stakeholders we have identified for this business:

1. Customers: Patients and healthcare providers

2. Investors: Stockholders, financial institutions and venture capitalists

3. Employees: Scientists, researchers, administrative and managerial personnel

4. Suppliers: Pharmaceutical, biotechnology and radiopharmaceutical industry partners

5. Regulatory Authorities: Governance and regulatory bodies

6. Community: Local government and community organisations

Value Proposition

A value proposition explains the unique value and/or benefits that an organisation provides to its customers, partners, stakeholders and the overall market. It outlines what makes a company like Advanced Accelerator Applications S.A. different from its competitors, along with what it can offer that key competitors cannot.

A corporate value proposition can be used with the competitive advantages section of this report in order to better understand Advanced Accelerator Applications S.A. and its position within the marketplace.

Advanced Accelerator Applications S.A. is a company that provides acceleration services to businesses and research institutions. The company offers a suite of services that include high-performance computing, simulation, and data analytics. The company's services are designed to help businesses and research institutions speed up their research and development processes.

Competitive Advantages

Competitive advantages are unique attributes, strategies, resources, or capabilities that allow an organisation to outperform its competitors and achieve superior market position and profitability.

Competitive advantages for the business include the following:

Proprietary Technologies: Advanced Accelerator Applications S.A. has developed proprietary technologies, such as its proprietary radionuclides and radiochemistry processes, which give it an edge over its competitors.

Innovative Technologies: Advanced Accelerator Applications S.A. has developed innovative technologies and products, such as the first-of-its-kind PET-CT imaging contrast agent, which gives it a competitive advantage.

Broad Portfolio: The company has a broad portfolio of products and services, including radiopharmaceuticals, radiochemistry services, and PET imaging agents, which provides it with a competitive edge.

Global Presence: Advanced Accelerator Applications S.A. has a presence in more than 40 countries, which helps it expand its reach and gain a larger share of the market.

Strategic Partnerships: Advanced Accelerator Applications S.A. has strategic partnerships with other leading companies in the industry, such as Siemens and Bayer, which give it access to new markets and technologies.

Customers & Cohorts

As part of this competitive intelligence study, we have identified the main customers of the organisation.

These include the following cohorts:

Health care providers
Medical research centers
Pharmaceutical companies
Hospitals
Universities
Government agencies
Private organisations
Biotechnology companies
Diagnostics companies
Medical device manufacturers

Market Trends

Market trends can impact an organisation by influencing consumer behavior, altering supply and demand dynamics, and affecting the organisation's ability to remain competitive in the market.

As part of this study, we have identified a number of potential short-term to medium-term trends that could impact the organisation. These include the following:

Growing Demand for Radiopharmaceuticals: As nuclear medicine becomes increasingly popular in diagnostic and therapeutic applications, demand for radiopharmaceuticals is also expected to increase. This is likely to be beneficial for Advanced Accelerator Applications S.A., as the company produces a variety of radiopharmaceuticals for use in diagnostic imaging and therapeutic treatments.

Increasing Prevalence of Nuclear Medicine: The increasing prevalence of nuclear medicine is expected to benefit Advanced Accelerator Applications S.A. as the company produces a variety of radiopharmaceuticals for use in diagnostic imaging and therapeutic treatments. This trend is likely to help Advanced Accelerator Applications S.A. increase its market share.

Advancement of Radiopharmaceutical Technology: The development of more efficient and effective radiopharmaceuticals is expected to benefit Advanced Accelerator Applications S.A. as they have the expertise and experience in creating such products. This could help the company remain competitive in the market.

Expansion of Nuclear Medicine Facilities: With the expansion of nuclear medicine facilities, Advanced Accelerator Applications S.A. is likely to benefit as they have the resources to meet the increased demand for radiopharmaceuticals. This could help the company to increase its sales and profits.

Key Performance Indicators

Below is a list of KPI's that we have identified as being strategically relevant to this organisation:

Financials (BETA)

The key financials for Advanced Accelerator Applications S.A. include income statements, which can be found in their annual reports. These financial statements provide information on the organisation's financial performance and health, including revenue, expenses, and profits. This information, along with other indicators are used by investors, analysts and other stakeholders to evaluate the company's performance and future prospects.

Where a financial does not match, we have included those of the parent company (if a listed entity). If the financials are missing please contact us and we will prioritise the update.

Key Personnel

Income Statement

Highlights

Top-level corporate stats and financial highlights for the listed entity, include:

Share Performance

Below is the current (EOD) share performance for the company, or its listed parent:

Potential Products/Services

As part of this study we have attempted to prognosticate potential products and/or services this organisation could develop in the short to medium-term.

Radiopharmaceuticals: Advanced Accelerator Applications S.A. could create radiopharmaceuticals to be used in nuclear imaging and therapy. These radiopharmaceuticals would be specifically designed to target specific diseases and provide more accurate diagnoses.

Cancer Treatment Solutions: Advanced Accelerator Applications S.A. could develop new cancer treatment options that incorporate their existing products and technologies. This could include personalised cancer therapies that use a combination of radiopharmaceuticals, radiotherapy, and chemotherapy.

Diagnostic Imaging Solutions: Advanced Accelerator Applications S.A. could develop diagnostic imaging solutions that leverage their existing imaging technologies. This could include computer-aided imaging solutions that provide more accurate diagnoses.

Clinical Trials: Advanced Accelerator Applications S.A. could develop clinical trials for their existing products and services. This would provide a way to test the efficacy of their products and services and provide evidence-based data to physicians and patients.

Education and Training Services: Advanced Accelerator Applications S.A. could develop educational and training services to ensure proper usage of their products and services. This could include courses and seminars on the proper use of their products and services.

Potential Synergies

Using our product and portfolio-matching algorithm, we have determined that the following organisations have potential synergies with the company:

1. Pharmaceutical companies such as Novartis, Pfizer, and Bristol-Myers Squibb
2. Medical device companies such as Medtronic and Siemens
3. Diagnostic companies such as GE Healthcare, Philips Healthcare, and Siemens Healthineers
4. Medical imaging companies such as Siemens Medical Solutions USA, Inc. and Philips Healthcare
5. Biotechnology companies such as Biogen and Genentech
6. Hospitals and research institutions such as Mayo Clinic, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center
7. Universities and research institutes such as Harvard Medical School and Stanford University

Porter's Five Forces

Created by Harvard Business School Professor Michael Porter in 1979, Porter's Five Forces model is designed to help analyse the particular attractiveness of an industry; evaluate investment options; and better assess the competitive environment.

The five forces are as follows:

Competitive rivalry
Supplier power
Buyer power
Threat of substitution
Threat of new entries

The 5 forces are:

1. Threat of new entrants: The threat of new entrants is HIGH if there are few barriers to entry into the market and if there is strong competition from existing players. Advanced Accelerator Applications S.A. scores HIGH on this force.

2. Bargaining power of buyers: The bargaining power of buyers is HIGH if there are many buyers in the market and if they are able to easily switch to another supplier. Advanced Accelerator Applications S.A. scores HIGH on this force.

3. Bargaining power of suppliers: The bargaining power of suppliers is HIGH if there are few suppliers in the market and if they are able to charge HIGH prices. Advanced Accelerator Applications S.A. scores HIGH on this force.

4. Threat of substitute products: The threat of substitute products is HIGH if there are many substitute products available in the market and if they are close substitutes. Advanced Accelerator Applications S.A. scores HIGH on this force.

5. Rivalry among existing players: The rivalry among existing players is HIGH if there are many players in the market and if they are all competing for the same customers. Advanced Accelerator Applications S.A. scores HIGH on this force.

PESTLE Analysis

This PESTLE analysis is a strategic planning tool that assesses key external factors affecting the organisation, including the following:

Political
Economic
Social
Technological
Legal
Environmental

Each of these factors is analysed to determine their impact on the organisations strategy, objectives, and operations.

By utilising a PESTLE analysis, the organisation can make better decisions and develop strategies to address potential risks and opportunities.

CATWOE Analysis

The CATWOE analysis is used to investigate each stakeholders perspectives in order to enable the business to make informed decisions.

The CATWOE analysis is a problem-solving tool consisting of six elements:

Customers
Actors
Transformation process
World view
Owners
Environmental constraints

We view the CATWOE as being most useful when used in conjunction with other problem-solving tools such as a SWOT analysis.

Customers: Advanced Accelerator Applications S.A. provides a wide range of radiopharmaceutical products and services to healthcare professionals, including nuclear medicine physicians, hospital and clinic radiology departments, and radiopharmacies.

Actors: The primary actors involved in Advanced Accelerator Applications S.A. are its employees, customers, and suppliers. The company's employees are responsible for the production, marketing, and delivery of its products and services. Customers are the end users of the products and services offered by Advanced Accelerator Applications S.A., while suppliers provide the necessary raw materials and other resources needed for the production and delivery of the company's products and services.

Transformation process: Advanced Accelerator Applications S.A. is responsible for the development, production, marketing, and delivery of radiopharmaceutical products and services. The company develops its products and services through research and development, and then produces them using its manufacturing facilities. The company then markets and distributes its products and services to customers, and provides technical support and customer service.

World view: Advanced Accelerator Applications S.A. is committed to providing high-quality, safe, and effective radiopharmaceutical products and services that meet the needs of its customers. The company strives to be a leader in the field of radiopharmaceuticals and to be a reliable partner in providing solutions to healthcare professionals around the world.

Owners: Advanced Accelerator Applications S.A. is a publicly-traded company, with shares listed on the Euronext Paris Stock Exchange. The company is majority-owned by Novartis, a global healthcare company.

Environmental constraints: Advanced Accelerator Applications S.A. is subject to various laws, regulations, and standards related to the production and distribution of radiopharmaceuticals. The company is also subject to various international trade regulations, as well as environmental regulations related to the production and

SWOT Analysis

This SWOT analysis is a strategic planning tool used to assess the strengths, weaknesses, opportunities and threats of the Advanced Accelerator Applications S.A. business.

When creating this SWOT the team at Platform Executive have taken into consideration the corporate strategy; brand; key financials; the competitive landscape; along with the products and/or services offered.

To offer increased context for future innovation and product development we also consider the historical context for the business and industry; and perceived direction of travel.

Upon researching the company, we have uncovered a number of strategic and operational strengths, weaknesses, opportunities and threats.

Strengths

Below is a list of the strengths we have identified for the business:

1. Advanced Accelerator Applications S.A.'s (AAA) unique selling proposition is its focus on cancer patients and its development of targeted therapies using radioisotopes.

2. AAA has a strong research and development team that is constantly innovating new ways to target cancer cells and improve patient outcomes.

3. AAA has a strong manufacturing infrastructure and supply chain, which ensures a consistent supply of high-quality radioisotopes for its therapies.

4. AAA has an experienced commercial team that is well-positioned to drive sales and market adoption of its therapies.

Opportunities

Below is a list of opportunities we have identified for the business:

1. Expand into new markets: Advanced Accelerator Applications S.A. could take advantage of the growing demand for medical imaging and radiopharmaceuticals by expanding into new markets. This could include focusing on new geographic regions, such as emerging markets in Asia, or focusing on new customer segments, such as private hospitals.

2. Increase focus on innovation: Advanced Accelerator Applications S.A. should focus on developing new products and services that meet the needs of its current and potential customers. This could involve investing in research and development to develop new technologies, such as a new form of radiopharmaceuticals, or expanding its product portfolio to include new services, such as a subscription-based imaging platform.

3. Improve operational efficiency: Advanced Accelerator Applications S.A. should focus on improving operational efficiency to reduce costs and increase profitability. This could involve streamlining processes and procedures, such as automating certain tasks, or introducing new technologies, such as artificial intelligence, to reduce manual labour.

4. Enhance customer experience: Advanced Accelerator Applications S.A. should focus on enhancing the customer experience by improving customer service and implementing new customer engagement strategies. This could involve using customer feedback to develop new products, providing personalised customer support, or offering loyalty programs to reward loyal customers.

Weaknesses

Below is a list of the weaknesses we have identified for the business:

1. Lack of a clear value proposition: Advanced Accelerator Applications S.A. (AAA) does not have a clear value proposition. This makes it difficult for the company to communicate its unique selling points to potential customers.

2. Limited market reach: AAA’s products are only available in Europe and the company has no plans to expand into other markets. This limits the potential growth of the company.

3. Lack of differentiation: AAA’s products are not differentiated from its competitors. This makes it difficult for the company to compete on price and to attract new customers.

4. High reliance on government contracts: AAA is heavily reliant on government contracts. This exposes the company to political risk and could lead to a decline in revenue if government budgets are cut.

Threats

Below is a list of the threats we have identified for the business:

1. Regulatory Risk: Advanced Accelerator Applications S.A. (AAA) is subject to the risk of changes in regulations that might adversely affect its product portfolio, production processes and marketing strategies. Examples include changes in taxation laws, import/export regulations and intellectual property rights.

2. Competitor Risk: With the fast-paced growth of the medical imaging industry, AAA faces competition from other players, both domestic and international. These competitors may offer superior products, better pricing and/or more advanced services.

3. Technical Risk: AAA’s products depend on the latest developments in medical imaging technology and the company is vulnerable to the risk that the technology may become obsolete, either due to advances in the industry or changes in customer preferences.

4. Financial Risk: AAA’s financial performance is subject to the risk of macroeconomic factors, such as inflation, currency fluctuations and changes in interest rates. In addition, AAA’s financial health is dependent on its ability to secure sufficient funding to finance its operations and development projects.

5C Analysis

The 5C Analysis is a marketing framework that can be used to provide insight into the key drivers of success, as well as the risk exposure to various environmental factors.

This (concise) 5C analysis examines the external and internal environment for Advanced Accelerator Applications S.A.. It includes analysing the company's customers, competitors, collaborators, context, and capabilities. We have produced this short analysis to identify potential opportunities and threats to Advanced Accelerator Applications S.A., as well as areas where the company needs to improve its operations or strategy.

Company: Advanced Accelerator Applications S.A. (AAA) is a multinational biopharmaceutical company dedicated to producing innovative, patient-centric treatments for cancer, autoimmune diseases, and other life-threatening illnesses.

Collaborators: AAA partners with a variety of pharmaceutical companies, universities, and research institutions to develop and manufacture products that are safe and effective. They also work closely with regulatory authorities to ensure compliance with industry standards.

Customers: AAA’s customers are mostly medical professionals, healthcare providers, and patients who benefit from the company’s products.

Competitors: AAA faces strong competition from other biopharmaceutical companies that provide similar treatments.

Content: AAA produces a wide range of products, from radiopharmaceuticals to immunotherapies. Their portfolio contains novel drugs that are designed to target specific diseases, as well as more general treatments that are designed to provide relief from a variety of ailments. AAA is also committed to providing educational resources and support services to their customers.

MOST Analysis

The MOST analysis framework is commonly used to identify an organisation's strategic goals, assess its strengths and weaknesses, and develop a plan to achieve its objectives. This analysis helps organisations to focus on what they want to achieve and how to achieve it, while also identifying potential roadblocks or obstacles that may arise along the way.

Mission
Objectives
Strategy
Tactics

We have created this analysis from a 3rd person perspective.

Innovation Scorecard

As part of our research and analysis activity, the team at Platform Executive assesses and then benchmarks businesses and the industry verticals in which they operate using a proprietary scoring mechanism.

First, we allocate a score of A-E for the industry vertical, gauged on the key organisations operating within the space; and then score the individual business using a 1-5 score.

A score of D-E within an industry means that it is potentially ripe to be disrupted by a new entrant into the marketplace; and/or vulnerable to technological change.

Likewise, a high score of 4-5 for the company in question indicates that in the view of the analysis team it lags behind notable businesses in terms of innovation and product pipeline.

Below is a guide to each score:

Industry score:

A	The industry is amongst the most innovative; with the leading players all driving the sector forward. Example industry: PaaS
B	The industry and its leading players have a good track record of innovation; and can quickly react to change. Example industry: Pharmaceutical
C	Companies operating within the sector have adequate levels of innovation; and engage in R&D activities when appropriate. Example industry: FMCG
D	Businesses operating in the industry do not invest enough time and resource into innovation. The sector is stagnant and a good candidate for disruption. Example industry: Retail Banking
E	The major players in the sector seem to lack suitable product development roadmaps; and as a result the sector is highly vulnerable to industry change. Example industry: Publishing

Company score:

1	The business is amongst the leading players in terms innovation and product pipeline. This will fulfil and reinforce the operations of the business in the medium to long-term.
2	The business has a good track record of innovation, in terms of its products and/or its business model. It is therefore more likely to be able to react and adapt to any changes to the industry.
3	The business is deemed to have an adequate innovation plan, build on research and development and sustainability where appropriate. The business has a product development strategy.
4	The business needs to invest more resource and/or intellectual capital in product development, pipelines and/or its business model. The business is at risk of stagnation.
5	The business seems to lack a suitable product development roadmap; and as a result is vulnerable to any notable industry change and/or new entrants in the marketplace.

The team at Platform Executive has judged Advanced Accelerator Applications S.A. as having an innovation score of B3.

Appendices

The appendices section of this report contains supplementary information that the team at Platform Executive deems helpful in providing a more comprehensive understanding of the report's contents.

This information is not considered an essential part of the study but serves as a useful supplement to the main text.

Methodology

This study on Advanced Accelerator Applications S.A. forms part of our series of competitive intelligence reports, which focuses on 10,000 of the largest corporates.

The information and data included are updated on a timely schedule to ensure that our Premium members receive the most up to date information .

The report is based on information and learning from the following sources:

Corporate websites
Proprietary research databases
SEC Filings
Corporate press releases
News articles
Financial data API's
Product-matching algorithm

Further Information

Premium members: If you cannot find the desired information or data set for the business you are researching then please reach out to our research and analysis team. We can tailor reports to meet your requiremnents, with a fast turnaround time.

If you require a bespoke study on a particular industry vertical, or marketplace we may also be able to help.

Disclaimer

Reproduction of the content produced in this report is prohibited without the prior permission of the publisher, Platform Executive Pty Ltd.

The facts of this report have been gathered in good faith from both primary and secondary sources. It is believed to be correct at the time of publication, but cannot be guaranteed. As such Platform Executive can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

Changelog

Premium members: To request a priority update to this report, please contact us. Our standard turnaround time is normally 48 hours.

The changelog for this report can be found below, complete with the next scheduled update:

v1.1: Initial load of report
Date: 1st March 2023

Key Financials added (BETA)
Date: 17th March 2023

Next scheduled update: 25th April 2023

Industry Keywords

Related keywords:

Nuclear Medicine Oncology Pharmaceuticals Radiopharmaceuticals

Swatch Group

Prudential Bancorp Inc